A Mid-To-Large Omnichannel Retailer Six Months From Renewing A $45M Five-Year Strategic Tier-1 Vendor Contract — The Vendor Having Missed Three Of The Last Five Implementation Milestones, The CIO And CFO And CPO Not Yet Aligned On Whether To Renew, Renegotiate, Or Replace. An Independent Vendor Contract Review Reconstructed The Milestone-Miss Record, Quantified The Renegotiable Value, And Produced A Single Board-Defensible Renewal Posture Inside The Pre-Renewal Commercial Leverage Window.
Paused renewal commitment discussions pending forensic milestone-miss reconciliation. Communicated to the vendor that renewal terms would be contingent on resolution of the milestone-miss pattern. Initiated parallel replacement evaluation as a leverage instrument — not as a commitment to switch.
Reconstructed the milestone-miss record across the most recent implementation wave. Quantified the renegotiable value: $4–6M across the remaining commitment. Identified an additional $3–5M of implementation contingency available for re-allocation to vendor-side risk pricing.
Reframed milestone definitions in renegotiated terms from activity-based to integrated-outcome-based. Introduced vendor-side risk pricing for integrated-outcome milestones. Aligned CIO, CFO, CPO, and Chief Supply Chain Officer on a single board-defensible renewal posture.
Established quarterly vendor performance reviews anchored to integrated-outcome milestones across the renewed term. Built standing parallel-evaluation discipline for all Tier-1 vendor relationships approaching renewal. Embedded ongoing independent validation through the next implementation wave.
Complete forensic findings, root cause hierarchy, 90-day stabilization roadmap, and assurance operating model. Written for Board-level and executive review.
PDF · Full detail · No form required
Findings shared only with the commissioning executive.
No vendor ties. Evidence-based, free from internal bias.
Briefing is complimentary. Scope agreed before any commitment.
A Member-Owned Electric Cooperative Carrying $200M Of Active Capital Across Seven Concurrent Programs — Each Reporting Healthy At Program Level — With A General Rate Case Twelve Months Out And A Member-Board Capital Plan Review Behind It. An Independent Portfolio Review Surfaced Five Cross-Program Sequencing Dependencies And Produced A Defensible Re-Sequenced Capital Plan Ahead Of Regulatory Filing.
A Mid-To-Large Omnichannel Retailer Six Months From Renewing A $45M Five-Year Strategic Tier-1 Vendor Contract — The Vendor Having Missed Three Of The Last Five Implementation Milestones, The CIO And CFO And CPO Not Yet Aligned On Whether To Renew, Renegotiate, Or Replace. An Independent Vendor Contract Review Reconstructed The Milestone-Miss Record, Quantified The Renegotiable Value, And Produced A Single Board-Defensible Renewal Posture Inside The Pre-Renewal Commercial Leverage Window.
Two consecutive missed phased go-lives. A third re-baseline being drafted. A new CIO inheriting the trajectory. An independent recovery diagnostic produced a defensible recovery posture in 4 weeks — protecting an additional $18–22M in projected cost exposure and routing clinical-safety risk back to clinical governance.
